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| INTRODUC TI ON
Kidney transplant (KT) remains the best option for renal replacement therapy, 1 although its expansion is threatened due to the shortage of available grafts. Donation after circulatory death (DCD) may effectively increase the pool of donors. 2, 3 However, kidneys obtained from DCD donors experience increased ischemic stress after the cessation of cardiorespiratory function, a circumstance that negatively affects short-and long-term graft viability and recipient survival. 4, 5 In 1995, the so-called Maastricht classification was
proposed to address the large heterogeneity across DCD donors in terms of procurement practices and associated outcomes. 6 Organs from uncontrolled DCD (uDCD) donors (Maastricht categories I and II) are exposed to more ischemic damage than those obtained after termination of life support (controlled DCD [cDCD] , or Maastricht category III). The longer period of severe hypoperfusion resulting from an unexpected cardiorespiratory arrest (CA) and unsuccessful advanced cardiopulmonary resuscitation (aCPR) likely accounts for this difference. 4 Most previous studies have been focused on KT obtained from cDCD donors, because this is the most widespread practice, or jointly analyzed cDCD and uDCD programs. This methodological variability might explain the disparate rates of delayed graft function (DGF) and primary graft nonfunction (PNF) reported in the literature. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Focusing on the results of uDCD programs, it is clear that notable differences exist in terms of donor acceptance criteria, practices of donor life support and organ perfusion, and immunosuppression regimens; these differences hamper the interpretation of the reported outcomes.
5
An active uDCD program was established at our institution >10 years ago. Donors are patients who experienced CA in the street or at their home and received unsuccessful aCPR. They are transferred to our center via ambulance or helicopter and uniformly managed with normothermic extracorporeal membrane oxygenation (nECMO) as the organ preservation strategy. [17] [18] [19] [20] [21] In this study, we analyzed the long-term outcomes of KT using organs from these uDCD donors maintained under homogeneous preservation practices and compared them with outcomes obtained during the same period from DBD with standard criteria donors.
| MATERIAL S AND ME THODS

| Study population and setting
We performed a single-center observational cohort study that in- 22 Clinical data were retrospectively collected by means of a standardized case report form. Patients in both groups were followed until June 2017, graft loss, or death, whichever occurred first.
The study was primarily aimed at comparing graft survival (both uncensored and censored by death), recipient survival, and graft function between the uDCD and DBD groups. As a secondary aim, we assessed pretransplant factors predicting deathcensored graft survival and recipient survival within the uDCD group.
The study was performed in accordance with the ethical standards laid down in the declarations of Helsinki and Istanbul.
The local clinical research ethics committees approved the study protocol. The need for specific informed consent was waived due to the retrospective and noninterventional nature of the investigation.
associated with graft loss in the uDCD group (hazard ratio: 1.91; P = .058), whereas the occurrence of DGF showed no significant effect. uDCD KT under nECMO support resulted in similar graft function and long-term outcomes compared with KT from standard criteria DBD donors. Increased donor age could negatively affect graft survival after uDCD donation.
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| uDCD donors (Maastricht category II)
The uDCD program was established at our institution in June 2005 17 and has been described elsewhere. [18] [19] [20] [21] The process is activated once a potential donor is identified on the fulfillment of the following criteria:
(1) the donor has sustained an unexpected and witnessed out-of-hospital CA, (2) aCPR provided by emergency medical services has been applied for at least 30 minutes, and (3) aCPR has been deemed unsuccessful by the attending team. Acceptance criteria for considering a patient with irreversible CA as a potential uDCD donor are shown in Table 1 . At that time, the potential donor is transported to the hospital via an intensive care ambulance or medical helicopter (depending on the geographical distance from the point where the CA took place), whereas aCPR is maintained as per national protocols. In the hospital, following a legally required "no-touch" period of at least 5 minutes, death is declared and certified. For the purpose of preserving organ viability, Spanish uDCD consensus allows for a restart of organ preservation with a few minutes of cardiac compression and mechanical ventilation until the initiation of nECMO confined to the abdominal region. 4, 5 Once consent to donation is given by the relatives, the kidneys are obtained. Throughout the entire study period, we used regional perfusion confined to the abdominal region by nECMO and cold storage for ex vivo graft preservation. The procured kidneys are perfused with preservation solution and carefully explored on a back table. The criteria applied by the urological surgery team to assess graft viability include macroscopic appearance and consistency (discarding those with overall or patchy cyanotic appearance), occurrence of changes in color and macroscopic appearance after graft flushing, and discharge of preservation solution through the renal vein.
| Study definitions
Biopsy-proven acute graft rejection (BPAR) was suspected with an acute increase in serum creatinine level and confirmed by subsequent histological assessment. DGF denoted the need for dialysis within the first week after KT. Death-censored graft loss was defined by the permanent return to dialysis or retransplant. Graft loss encompassed these outcomes as well as recipient death. Patients 
| Immunosuppression regimen
Peak PRA ≥15%, n (%) 9 (3.8)
(1.7)
.160
Pretransplant conditions, n (%) CAPD, continuous ambulatory peritoneal dialysis; COPD, chronic obstructive pulmonary disease; DBD, donation after brain death; ESRD, end-stage renal disease; uDCD, uncontrolled donation after circulatory death.
| Assessment of graft function
Glomerular filtration rate (GFR) was estimated through the 4- 
| Statistical analysis
Quantitative data are given as the mean ± SD or the median with IQR values. Qualitative variables were expressed as absolute and relative frequencies. Categorical variables were compared by using the χ 2 test, whereas the Student t test or the Mann-Whitney U test were applied for continuous variables, as appropriate. Survival curves were plotted by using the Kaplan-Meier method, and differences between groups were compared with use of the log-rank test.
Multivariate Cox regression models with backward stepwise variable selection were used to evaluate the association between variables present at the baseline (ie, pretransplant) evaluation and graft and patient survival within the uDCD group. Models included all variables with P < .10 at the univariate level. Some clinically relevant factors were also forced into the multivariate models regardless of their univariate statistical significance. Collinearity among explana- nonrandomized design of our study, we calculated the propensity for receiving a graft from an uDCD (vs DBD) donor given the patient's baseline characteristics. This score was estimated by using a backward stepwise logistic regression model that included variables with univariate P < .10, and the fit of the resulting model was assessed by means of the Hosmer-Lemeshow test and the area under the receiving operator characteristic curve (AUC). The resulting propensity score was then used as a covariate in a multivariate model to adjust for potential baseline imbalances between study groups.
Statistical significance was set at P < .05. All the significance tests were 2-tailed. Analyses were performed with SPSS v. 20.0 (IBM Corp., Armonk, NY).
| RE SULTS
| Performance of the uDCD program
Of a total of 568 notifications of potential uDCD donors received at our center from June 2005 to December 2013, 255 (44.9%) were rejected due to lack of compliance with acceptance criteria (Figure 1 ).
The time elapsed from CA to the initiation of aCPR in the 264 accepted notifications was 11.2 ± 5.5 minutes (target <15 minutes).
Regarding the transportation mode, ambulance and helicopter were used in 206 (78.0%) and 58 (22.0%) potential donors, respectively.
Time from CA to hospital arrival was 72. Donor and recipient characteristics are described in Table 2 . Donors in the uDCD group were more commonly male and had higher serum creatinine levels at procurement, whereas recipients more commonly had underlying diabetic nephropathy and exhibited higher immunologic risk (as reflected by the higher prevalence of previous transplant and hepatitis C virus infection and the higher number of HLA mismatches). Regarding pretransplant comorbidities, a higher number of cardiovascular risk factors were observed in the uDCD group, including diabetes mellitus, dyslipidemia, and smoking. On the basis of these baseline variables, we estimated the propensity score for receiving a graft from a uDCD donor. The resulting score showed an excellent predictive capacity (AUC: 0.894; 95% CI: 0.865-0.922).
Regarding peritransplant variables, cold ischemia time was lower in the uDCD group (Table 3) (Table S1 ). In view of these events, prophylactic anticoagulation was introduced as standard practice in both groups beginning in November 2009 to minimize the risk of venous thrombosis. In addition, the performance of the first biopsy was systematically postponed to the third posttransplant week in the uDCD group. DGF was most common in the uDCD group, as was the median number of days of DGF. Surgical wound dehiscence was more common in the uDCD group, with no differences in other surgical complications ( Table 3 ). The 1-year rate of BPAR was higher in the DBD group, mainly at the expense of T cell-mediated episodes, with no differences in other late complications (Table 4 ).
| Graft survival
Mean follow-up was similar for the uDCD and DBD groups (65 months [IQR: 46-90] vs 72 months , respectively; P = .270). We found no significant differences in overall (uncensored) graft survival between the uDCD and DBD groups at 5-year (80.9% vs 85.6%) or 10-year follow-up (71.1% vs 70.8%, respectively; logrank test P = .403) (Figure 2A ). There were also no differences when graft survival was censored for patient death (5-year survival: 86.6% vs 88.9%; 10-year survival: 82.1% vs 80.4%; log-rank test P = .623) ( Figure 2B ). The lack of impact of the donor source on death-censored graft survival persisted after propensity score adjustment (HR:
0.75; 95% CI: 0.38-1.49; P = .419).
Multivariate analysis of risk factors for death-censored graft survival in the uDCD group is shown in 
| Patient survival
There were no statistically significant differences between the uDCD and DBD groups in terms of patient survival at 5 years (93.1% vs 95.8%) or 10 years (86.2% vs 87.6%; log-rank test P = .454) ( Figure 2C ). Propensity score adjustment did not alter this lack of impact (HR: 1.49; 95% CI: 0.58-3.85; P = .411). 0.98-8.03; P = .055) were found to predict patient survival in the uDCD group in the multivariate analysis (Table 6 ).
| Graft function
The evolution of graft function throughout the follow-up period is detailed in Figure 3 . Estimated GFR was significantly lower in the uDCD group compared with in the DBD group at month 1 (33. ATG, antithymocyte globulin; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DGF, delayed graft function; ESRD, end-stage renal disease; uDCD, uncontrolled donation after circulatory death. a Pretransplant diagnoses of malignancy include nonmelanoma skin cancer (n = 4), melanoma (n = 2), breast cancer (n = 2), lung cancer, colorectal carcinoma, renal cell carcinoma, seminoma, papillary thyroid carcinoma, parathyroid carcinoma, meningioma, and ovarian cancer (n = 1 each).
TA B L E 5 (Continued)
TA B L E 6 Univariate and multivariate analyses of factors present at the time of transplant predicting 10-year recipient survival in the uDCD group .767
Sex of donor, male, n (%) 3 (17.6)
(11.4)
.433
Donor serum creatinine >1.2 mg/dL, n (%) 9 (52.9)
(59.5)
.594
Recipient age, y (mean ± SD) 53.2 ± 11.9
47.4 ± 10.8
.035
Recipient age >50 y, n (%) 12 (70.6)
(43.6)
.032
3.17
1.12-8.99
.030
2.80 0.98-8.03
.055
Sex of recipient, male, n (%) 8 (47.1)
(60.5)
.278
Recipient weight, kg (mean ± SD)
76.1 ± 14.7
72.3 ± 15.3
.317
Etiology of ESRD, n (%) Diabetic nephropathy 8 (47.1)
(16.4)
.005
5.15
1.95-13.63
.001
3.93
1.49-10.39
.006
Nephroangiosclerosis 0 (0.0)
(13.2)
.238
Glomerulonephritis 2 (11.8)
(22.3)
.539
Polycystic kidney disease 1 (5.9)
(14.5)
.480
Chronic interstitial nephropathy 3 (17.6)
(15.5)
.734
Vasculitic or autoimmune disease 2 (11.8)
(4.5)
.209
Other 1 (5.9)
(13.6)
.706
Pretransplant renal replacement therapy, n (%) 17 (100.0) 218 (99.1)
1.000
Time on dialysis >24 mo, n (%)
(38.5)
.829
Hemodialysis as modality of renal replacement therapy, n (%) 
(38.2)
.230
Heart disease 1 (5.9) 23 (10.5)
1.000
Left ventricle ejection fraction <50% 1 (5.9)
(1.4)
.259
Peripheral arterial disease 1 (5.9)
(3.6)
.494 COPD 1 (5.9)
(1.4)
.
259
(Continues)
| D ISCUSS I ON
In this study, we show that our uDCD program, based on donors with unexpected out-of-hospital CA and supported by nECMO limited to the abdominal region as the organ preservation strategy, was effective in obtaining viable kidneys for transplant. 4, 5 We also described the overall performance of the program, from the notifications of potential donors to the grafts effectively transplanted and their long-term outcomes. [17] [18] [19] [20] [21] More than half of the potential donors were discarded due to noncompliance with acceptance criteria, medical reasons, unsuccessful bypass connection, or, to a lesser extent, family refusal. Only 64.8% of kidneys recovered from effective donors were ultimately transplanted, a figure lower than that reported for DBD donors, although still effective as suggested by the fact that almost 20% of KT performed during the study period came from uDCD donors.
17,24
Ischemic stress likely accounts for the relatively high incidence of PNF (6.8%) and DGF (73.4%) observed in the uDCD group. [25] [26] [27] [28] [29] [30] Nevertheless, other groups have reported even higher rates of PNF, reaching 22% in certain series. The occurrence of DGF in KT recipients from uDCD donors had no apparent impact on short-or long-term graft function or survival, unlike outcomes reported for DBD donors. 11, [37] [38] [39] [40] [41] This discordance might be explained by the immunosuppression regimen used in the uDCD group, based on ATG induction and with a delayed introduction of tacrolimus, which would have contributed to amelioration of ischemia-reperfusion injury. 42 It has been proposed that the pathogenesis of DGF may differ according to the type of donor, with a predominance of ischemic injury in DCD and alloimmune phenomena in DBD, thus supporting the protective role of immunosuppression. 14, 16, 43 Accordingly, despite uDCD recipients having higher immunologic risk, the rate of acute rejection in our experience was 
1.000
Previous transplant, n (%) 0 (0.0)
(6.4)
.607
Peak PRA ≥15%, n (%) 1 (5.9)
(3.2)
.808
HLA mismatches ≥ 4, n (%)
12 (70.6)
(82.3)
.326
Cold ischemia time, h (mean ± SD)
11.6 ± 3. 
1.000
ATG, antithymocyte globulin; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DGF, delayed graft function; ESRD, end-stage renal disease; uDCD, uncontrolled donation after circulatory death.
a Pretransplant diagnoses of malignancy include nonmelanoma skin cancer (n = 4), melanoma (n = 2), breast cancer (n = 2), lung cancer, colorectal carcinoma, renal cell carcinoma, seminoma, papillary thyroid carcinoma, parathyroid carcinoma, meningioma, and ovarian cancer (n = 1 each).
b Pretransplant diabetes mellitus was not included into the model due to the presence of significant collinearity (variance inflation factor = 4.397).
TA B L E 6 (Continued) lower than that in the DBD group likely due to the systematic use of ATG as induction therapy.
One relevant result was the lack of significant differences between the uDCD and DBD groups in death-censored graft survival at 10 years. Despite some initial controversy, some groups have failed to find differences between uDCD and DBD donors in terms of graft survival at 10 years from transplant. We found a 10-year death-censored graft survival rate (86.6%) higher than rates previously reported (50%-72%). [49] [50] [51] a trend toward better graft survival was noted for recipients with polycystic kidney disease likely due to a lower comorbidity burden and sensitization risk and to the lack of posttransplant recurrence of the underlying renal disease.
We also observed that patient survival was comparable across both groups, even in the long term. Recipients in the uDCD group had a more protracted recovery of renal function. Therefore, estimated GFR was lower during the first months, although no differences were observed thereafter in accordance with other authors. 29, 31, 32, 34, 39 A similar evolution was observed for 24-hour proteinuria. It has been reported that the function of uDCD grafts during the first 3 years may be worse than that of grafts in simultaneous pancreas-kidney transplant recipients.
Nevertheless, the lack of uniformity in organ preservation strategies and the unexpectedly high rates of acute rejection despite the use of ATG hamper the interpretation of such results.
28
Some limitations must be acknowledged. We chose to use as a comparison group a cohort of DBD recipients complying with the UNOS criteria for standard donor organs because optimal outcomes would be expected in this population. However, we found baseline imbalances and differences in immunosuppression regimens between the 2 groups. We attempted to correct for potential confounding factors by means of propensity score-based multivariate adjustment. The single-center nature of our study implied the application of uniform acceptance criteria and organ preservation and immunosuppression practices throughout the study period, although this also limits the external validity of our results.
In conclusion, graft and recipient long-term survival and graft function were comparable between KT recipients from uDCD and standard criteria DBD donors. Such favorable outcomes emphasize the benefits expected from applying uniform donor selection criteria with strict limits for ischemia times and from using organ preservation with nECMO and an ATG-containing immunosuppression regimen aimed at minimizing tacrolimus-associated kidney injury.
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